Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906513 | 0.90 | TDP1 (0.72) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL25305424 | 0.89 | TDP1 (0.70) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL28653646 | 0.89 | TDP1 (0.70) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL20537346 | 0.89 | TDP1 (0.70) | TDP1FOLH1CA12CA1CA2 | |
| Biotin SCHEMBL15104961 | 0.88 | TDP1 (0.68) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL12098624 | 0.84 | TDP1 (0.83) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL29531469 | 0.83 | TDP1 (0.61) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL9807479 | 0.82 | TDP1 (0.77) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL18779801 | 0.82 | TDP1 (0.78) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL564538 | 0.81 | TDP1 (1.00) | TDP1FOLH1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491818-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7423143-B2 | Nucleic acid labeling compounds | AFFYMETRIX. INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7291463-B2 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7282327-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7179905-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050287563-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6965020-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1589025-A2 | Nucleic acid labeling compounds | Affymetrix, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050164268-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1124838-B1 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX INC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040002595-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030232979-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030180757-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6596856-B2 | For probes, comprising a heterocycle condensed with a cyclic group such as ribofuranose derivative; biotin and 5-carboxyfluorescein derivatives | AFFYMETRIX, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020165372-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2000006771-A9 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX INC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20010044531-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2001-11-22 | — | — | US | disclosed |
| US-20010018514-A1 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-1124838-A2 | NUCLEIC ACID LABELING COMPOUNDS | Affymetrix, Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000006771-A2 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002595-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20030180757-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20050164268-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20010044531-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20050287563-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20010018514-A1 | NUCLEIC ACID LABELING COMPOUNDS | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20020165372-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
| US-20030232979-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | TDP1 241/4885FOLH1 1252/4885CA12 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.